Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
1.180
-0.060 (-4.84%)
At close: Sep 4, 2026, 4:00 PM EDT
1.200
+0.020 (1.69%)
After-hours: Sep 4, 2026, 7:57 PM EDT

Marker Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
3.553.556.593.313.511.24
Revenue Growth
-15.11%-46.19%99.06%-5.76%182.96%166.01%
Gross Profit
-5.26-8.25-6.88-7.11-8.45-26.55
Operating Income
-9.5-12.44-11.12-14.58-19.79-39.48
Net Income
-8.71-12.16-10.73-8.24-29.93-41.88
Earnings Per Share
-0.47-0.79-1.19-0.94-3.59-5.47
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
11.3316.0719.1915.1111.7842.35
Total Debt
-----11.87
Net Cash (Debt)
11.3316.0719.1915.1111.7830.48
Net Cash Growth
8.31%-16.28%27.01%28.26%-61.35%235.15%
Net Cash Per Share
0.611.052.141.721.413.98

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-9.76-12.01-10.91-16.44-26.97-27.28
Capital Expenditures
------3.13
Free Cash Flow
-9.76-12.01-10.91-16.44-26.97-30.41
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-148.28%-232.68%-104.33%-214.60%-240.64%-
Operating Margin
-267.95%-350.67%-168.69%-440.37%-563.28%-3179.32%
Pretax Margin
-245.94%-343.39%-162.06%-424.09%-562.85%-3372.68%
Profit Margin
-245.51%-342.96%-162.82%-248.76%-851.87%-3372.68%
FCF Margin
-275.09%-338.74%-165.53%-496.51%-767.66%-2449.11%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
5.557.015.0514.776.4663.58